ZBH
Zimmer Biomet Holdings Inc
NYSE: ZBH · HEALTHCARE · MEDICAL DEVICES
$79.58
+0.74% today
Updated 2026-06-05
Market cap
$17.13B
P/E ratio
22.95
P/S ratio
2.04x
EPS (TTM)
$3.86
Dividend yield
1.10%
52W range
$79 – $107
Volume
2.4M
WallStSmart proprietary scores
69
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+6.5
Quality
B6.0
Profitability
B7.3
Valuation
B+3/9
Piotroski F-Score
Weak
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$98.70
+24.03%
12-Month target
$85.98
+8.04%
Intrinsic (DCF)
$120.04
Margin of safety
+20.35%
2 Strong Buy6 Buy17 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $322.90M — positive
+ 20.35% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.94B | $7.39B | $7.68B | $8.23B | $8.41B |
| Net income | $231.40M | $1.02B | $903.80M | $705.20M | $238.10M |
| EPS | — | — | — | — | $3.86 |
| Free cash flow | $1.10B | $1.19B | $1.14B | $1.47B | $322.90M |
| Profit margin | 3.33% | 13.85% | 11.77% | 8.57% | 9.05% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | NOOR, JEHANZEB | Buy | 1,857 | — |
| 2026-05-29 | YI, SANG | Sale | 4,200 | $82.64 |
| 2026-05-29 | YI, SANG | Sale | 800 | $82.66 |
Peer comparison
Smart narrative
Zimmer Biomet Holdings Inc trades at $79.58. representing a P/E of 22.95x trailing earnings. Our Smart Value Score of 69/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.09, it sits in the grey zone. TTM revenue stands at $8.41B. with profit margins at 9.05%. Our DCF model estimates intrinsic value at $120.04.
Frequently asked questions
What is Zimmer Biomet Holdings Inc's stock price?
Zimmer Biomet Holdings Inc (ZBH) trades at $79.58, on a P/E of 23.0x and a P/S of 2.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Zimmer Biomet Holdings Inc overvalued?
Zimmer Biomet Holdings Inc carries a Smart Value Score of 69/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $120.04 versus the $79.58 price, a 20.4% margin of safety on a cash flow basis.
What is the price target of Zimmer Biomet Holdings Inc (ZBH)?
The 12-month analyst consensus target is $98.70, about 24.0% above the current $79.58. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Zimmer Biomet Holdings Inc (ZBH)?
Our DCF model estimates intrinsic value at $120.04, a +20.4% margin of safety versus today's $79.58. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Zimmer Biomet Holdings Inc's revenue?
Zimmer Biomet Holdings Inc's trailing twelve-month revenue is $8.41B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Zimmer Biomet Holdings Inc's Altman Z-Score is 2.09, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.04x
ROE5.17%
Beta0.47
50D MA$87.32
200D MA$92.87
Shares out0.19B
Float0.19B
Short ratio—
Avg volume2.4M
Performance
1 week+0.00%
1 month+4.34%
3 months-6.15%
YTD-2.88%
1 year—
3 years—
5 years—